Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.74 |
| ▸ | RECQL | P46063 | 5/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.74 |
| ▸ | TIMP3 | P35625 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 4/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | P2RY11 | Q96G91 | 6/20 | 0.64 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.64 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 4/20 | 0.64 |
| ▸ | P2RX1 | P51575 | 4/20 | 0.64 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.64 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.64 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.64 |
| ▸ | ENTPD3 | O75355 | 1/20 | 0.64 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17903265 | 0.92 | P2RY11 (0.78) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL18136595 | 0.92 | TIMP3 (0.78) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL6560525 | 0.91 | HSD17B10 (0.62) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL5501853 | 0.91 | P2RY11 (0.77) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL17903248 | 0.90 | RECQL (0.62) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL11593603 | 0.90 | TIMP3 (0.68) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL11758262 | 0.88 | HSD17B10 (0.58) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL18211298 | 0.88 | TIMP3 (0.64) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL11466435 | 0.87 | TIMP3 (0.76) | HSD17B10KMT2ARECQLTDP1TIMP3 | |
| SCHEMBL17903023 | 0.87 | HSD17B10 (0.56) | HSD17B10KMT2ARECQLTDP1TIMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486497-B2 | Treatment of immunocompromised conditions | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-11-08 | — | — | US | disclosed |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-07-07 | — | — | US | disclosed |
| US-8530448-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20100279958-A1 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | GLYCOMIMETICS, INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-7741312-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-08-31 | — | — | US | disclosed |
| US-7060685-B2 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1534725-A2 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | Glycomimetics, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20040254145-A1 | Compounds and methods for inhibiting selectin-mediated function | GLYCOMIMETICS, INC. (US) | 2004-12-16 | — | — | US | disclosed |
| WO-2003097658-A2 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | GLYCOMIMETICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194745-A1 | Compounds and methods for inhibiting selectin-mediated function | SELE, SELL, SELP | HSD17B10 3396/4885KMT2A 2401/4885RECQL 4815/4885 |
| US-20040254145-A1 | Compounds and methods for inhibiting selectin-mediated function | SELE, SELL, SELP | HSD17B10 3324/4885KMT2A 2423/4885RECQL 4814/4885 |
| US-20100279958-A1 | COMPOUNDS AND METHODS FOR INHIBITING SELECTIN-MEDIATED FUNCTION | SELE, SELL, SELP | HSD17B10 3324/4885KMT2A 2423/4885RECQL 4814/4885 |
| US-20160193294-A1 | COMPOSITIONS COMPRISING E-SELECTIN ANTAGONISTS AND USES THEREFOR | SELL, SELP, SELE | HSD17B10 4434/4885KMT2A 3656/4885RECQL 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.